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Summary
The overall value of initiating anti-retroviral therapy during the acute phase
of human immunodeficiency virus type 1 (HIV-1) infection remains unclear.
From a clinical perspective, the lack of data from controlled randomized
clinical trials limits understanding of long-term effects of treatment on the
clinical course of HIV infection. Based on available data, the impact of anti-
retroviral therapy during acute infection on the immune response against
HIV-1 is not particularly encouraging. Recent observations on the very early
depletion of lymphocyte reservoirs in the gastrointestinal tract may partially
explain the limited benefit of anti-retroviral therapy initiated during the acute
phase of HIV-1 infection. This may also help to explain the dichotomy
between early observations demonstrating apparent immunological benefit
with early anti-retroviral treatment that were associated none the less with
inability to control viral replication following treatment interruption.
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Human immunodeficiency virus type 1 (HIV-1) can infect
exposed individuals through mucosal surfaces or due to
direct inoculation into the bloodstream. The virus subse-
quently infects CD4+ T lymphocytes directly or as a conse-
quence of their interaction with virus-bearing dendritic cells
in the lymphoid tissues [1,2]. As with many other viral infec-
tions, the onset of clinical manifestations in HIV-infected
individuals is usually observed 2–4 weeks after exposure [3].
It has been reported that up to 90% of patients with acute
HIV-1 infection (AHI) report to a physician due to the pres-
ence of symptoms that are most often described as a flu-like
syndrome. The symptoms and signs seen in association with
acute HIV infection may include fever, lymphadenopathy,
pharyngitis, mucocutaneous lesions, myalgia/arthralgia,
headache, gastrointestinal symptoms (diarrhoea, nausea/
vomiting) and weight loss [4]. Notably, none of these find-
ings can be considered specific, although their persistence for
periods as long as 10 weeks and the presence of mucocuta-
neous ulcers are suggestive of AHI [5]. A particular challenge
in diagnosing AHI is the fact that the onset of symptoms
coincides typically with peak HIV viraemia [6], and usually
precedes by 2–3 weeks the development of HIV-specific anti-
bodies that are necessary for diagnosis using routine HIV
screening tests [7]. Therefore, the diagnosis of AHI is often
quite delayed (as long as 8–12 weeks after infection has
occurred), and this delay probably has a great impact on the
damage that occurs to the immune system before the initia-
tion of anti-retroviral therapy (ART). In addition, delays in
the diagnosis of AHI also prevent the implementation of
secondary prevention measures with a group of patients who
are at high risk of transmitting HIV during unprotected
sexual encounters, due at least in part to the high levels of
viraemia characteristic of this stage of infection [8,9].
Once the diagnosis has been made, additional challenges
include the absence of clear guidelines on whether to initiate
anti-retroviral treatment at this stage and the selection of an
initial regimen if treatment is elected. Published guidelines
for anti-retroviral therapy specifically note the lack of con-
sensus in this area. The US Department of Health and
Human Services (DHHS) guidelines (available at http://
aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf),
developed by the working group of the office of AIDS
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Research Advisory Council, and International AIDS Society
(IAS)–USA guidelines [10] are appropriately vague, because
of insufficient data to establish clear benefits of ART in acute
infection [11]. The British HIV Association (BHIVA) recom-
mends treatment for people with AHI for relief of symptoms
only. As a result, the decision to initiate ART is left to the
individual AHI patient and his or her health care provider.
Common laboratory parameters used to guide treatment
decisions for people with chronic HIV infection (such as
HIV RNA levels and CD4 counts) are not clearly of value for
acutely infected patients. As for choice of treatment regimen,
most available data is on the use of standard-of-care regi-
mens for chronic HIV infection, i.e. recommended first-line
regimens for treatment-naive patients as outlined in IAS–
USA as well as BHIVA guidelines [10].
These various considerations illustrate the clinical chal-
lenges associated with diagnosing AHI and initiating ART
treatment in a timely manner using an appropriate drug
regimen. Bearing these factors in mind, we will discuss what
is known of the impact current ART initiated during AHI
may have on the reconstitution of cellular-mediated
immune responses.
Impact of ART on cellular immune responses
The ability of HIV-1 to infect and to deplete the CD4+ T
lymphocyte subset has been considered for years to be the
hallmark of the pathogenesis of the acquired immunodefi-
ciency syndrome (AIDS) [12]. The ongoing depletion of this
pool of cells is thought to be the main cause of the progres-
sive impairment of the adaptive and innate immune
responses, the inability to control virus replication and the
onset of opportunistic infections and other AIDS-related
clinical manifestations.
Several studies have demonstrated that cellular-mediated
immune responses may play a central role in controlling the
initial burst of virus replication [13–15]. For years, CD8+ T
cell responses have been considered the main line of defence
during acute HIV infection and have been associated with
delayed disease progression [16].
Early observations by Rosenberg and collaborators in a
cohort of 10 untreated acutely infected individuals suggested
that detectable CD4+ T cell responses directed mainly against
the Gag p24 antigenic region were correlated inversely with
subsequent virus load [17]. Interestingly, the study reported
that three individuals who started ART at the time of AHI
diagnosis and before seroconversion were also able to
develop a strong anti-p24 lymphoproliferative response in
synchrony with a decrease in viral load. This was in striking
contrast with previous observations showing that chroni-
cally infected individuals lack strong lymphoproliferative
responses to HIV-1 antigens, despite suppressive anti-
retroviral therapy [18,19]. Subsequently, one study
compared the magnitude and breath of T cell responses in
three groups of individuals: (1) those receiving ART
pre-seroconversion (n = 19); (2) those treated post-
seroconversion and within 180 days of infection (n = 11);
and (3) those treated during chronic infection more than
180 days after infection (n = 10) [20]. After receiving ART
for 1 years, the pre-seroconversion group had the highest
significant detectable CD4 lymphoproliferative responses
[stimulation index (SI) = 43  13] compared to either the
post-seroconversion (SI = 29  10) or the chronically
infected groups (SI = 8  3). Oxenius and collaborators
observed similar beneficial effects from the initiation of ART
during acute infection on the CD4+ T cell compartment.
Their data indicated that the frequency of interferon (IFN)-
g-secreting CD4+ T cells was elevated in six patients up to
36 months post-treatment and directed mainly against
HIV-1 Env and Gag antigens [21]. Moreover, Cossarizza and
colleagues studied 18 individuals who received therapy
during AHI for 1 year and compared the profile of their
CD4+ Vb T cell receptor repertoire to that observed in ART-
treated chronically infected individuals and healthy non-
infected donors [22]. The clonality of the CD4+ T cell
population was apparently restored in AHI patients, but not
in the chronically infected individuals. These findings, again,
suggested a beneficial impact of ART initiated during AHI
on the CD4+ T cell population.
Several studies have also reported that the initiation of
ART during acute infection can boost CD8+ T cell responses
[20,21,23–25]. These data suggested that CD8+ T cell
responses were preserved by the initiation of therapy during
AHI. However, the frequency and breadth of cytotoxic and
IFN-g-secreting CD8+ T cells decreased over time with sup-
pression of viraemia, probably as a result of the lower
antigen stimulation. Another encouraging observation was
that the virus diversification in patients treated during AHI
was lower and therefore escape mutants had not been
generated, despite the strong cellular-mediated immune
responses [20].
Although the initial observations on the importance of
ART initiation in preserving T cell responses in acute infec-
tion was demonstrated in patients treated prior to serocon-
version [20], more recent studies suggest that ART may have
similar positive effects if initiated during the first 90 days
post-infection [25,26]. Furthermore, recent investigations by
Younes and colleagues on the breadth and magnitude of
CD4+ T cell responses by lymphoproliferation and class-II-
tetramer assays suggest that initiation of ART prior to sero-
conversion may impact negatively the maturation of HIV-
specific IFN-g-secreting CD4+ T cells as a consequence of the
limited time for interaction of antigen-presenting cells with
virus due to low antigenaemia [26].
With respect to duration of therapy, Oxenius and col-
laborators suggested that even a short course of ART treat-
ment initiated during AHI and continued for up to
24 weeks post-infection could exert beneficial effects on the
longevity and breadth of CD8+ and CD4+ T cell responses
[21].
TRANSLATIONAL MINI-REVIEW SERIES ON INFECTIOUS DISEASE
C. B. Hicks et al.
212 © 2007 British Society for Immunology, Clinical and Experimental Immunology, 149: 211–216
Impact of T cell responses generated under
AHI–ART on virus load
A consistent finding among individuals treated during AHI
has been higher proliferative capacity and frequency and
breadth of IFN-g- and interleukin (IL)-2-secreting T cells in
the groups receiving ART during AHI. This outcome was
observed independently of the duration of therapy, ranging
from 12 weeks [27] to 98 weeks [28]. Based on these findings
and those outlined in the previous section, indicating that
ART initiation within 90 days of infection preserved strong
T cell responses, one can hypothesize that subsequent treat-
ment interruption in these subjects might result in control of
HIV infection. Although viral control was demonstrated in
three of 14 individuals studied by Rosenberg and colleagues
[17], subsequent studies did not observe consistent viral
control following treatment interruption. Therefore, despite
preservation of cellular immune responses, initiation of ART
during AHI has not shown a consistent and significant
impact on decreasing viral rebound following treatment
interruption [27–30].
In summary, there are no clear data indicating that early
initiation of ART during AHI lowers the viral set-point or
delays disease progression following treatment interruption.
Controlling virus replication: a multi-faceted picture
The simplest potential reason for the inability to demon-
strate control of virus replication following ART interrup-
tion in patients treated during AHI is that the focus on
cellular-mediated immune responses as the key factor in
controlling HIV-1 replication may be incorrect. Indeed, this
relationship may not be central, and other components of
the immune response against HIV-1, as well as genetic
factors, could correlate with protection from infection
and/or disease progression [31].
If an overly narrow focus on cellular responses is a limiting
factor in understanding viral control, consideration of both
humoral and innate immunity may be important. Both
responses can be influenced positively by ART initiated
during AHI [32,33], but these factors may still not be suffi-
cient for control of virus replication following treatment
interruption.
As for other factors, even large cohort studies have been
unable to establish whether genetic factors, such as selected
HLA alleles and killer inhibitory receptor (KIR) haplotypes,
may contribute to the control of virus replication [34–36] or
whether they may have synergistic effects with the initiation
of ART during AHI.
ART-preserved cellular immunity: reasons for failure
Lack of a clear understanding regarding which factors are
important in control of viral replication limits the ability to
discern which parameters should be studied to assess the
effect of ART initiated during AHI [31]. Consideration of
data on T cell responses in individuals who control HIV-1
replication successfully without ART for up to 18 years
post-infection is illuminating. Viral control in these ‘long-
term non-progressor’ patients (LTNP) may not relate to a
single factor such as proliferative capability and/or single
cytokine production. Migueles and colleagues demon-
strated that the preservation of proliferative capability and
perforin production of CD8+ T lymphocytes set LTNP
apart from those who do not control virus replication [37].
Betts and collaborators recently reported a higher fre-
quency and breadth of CD8+ T cell responses with a multi-
functional profile in LTNP compared with subjects who do
not control virus replication successfully [38]. Both studies
revealed that the quality of cellular-mediated immune
responses may be more important than their mere fre-
quency or breadth. One could argue that even these param-
eters simply reflect the preservation of CD4+ T cell
responses that sustain other cellular, humoral and innate
components of the anti-viral responses. However, the ques-
tion of how cellular immune responses are preserved in a
limited number of infected subjects, and not in others,
remains.
One hypothesis is that the immune responses involved in
control of virus replication after treatment interruption
may be compared to those described as a recall response
after antigen-priming of the immune system, although
virus replication and therefore antigen stimulation still
occur during the latent phase of HIV-1 infection [12,39].
Janssen et al. demonstrated the importance of CD4+ T cells
providing the correct signal to the CD8+ T cell compart-
ment during the priming of the immune responses, as the
recall CD8+ T responses are impaired in the absence of this
interaction [40]. In the course of HIV infection, the matu-
ration and the functionality of CD8+ T cells are impaired
[41–45], reminders that the two fundamental effects of HIV
infection on the immune system are severe depletion of
CD4+ T lymphocytes and persistent cellular activation.
Accordingly, this raises the question: ‘is ART initiated
during AHI effective in preventing loss of CD4+ T lympho-
cytes that may be one of the key factors in correctly priming
the immune system?’
Loss of CD4+ T cells during AHI
The preferential infection of anti-HIV-specific memory
CD4+ T cells during the course of HIV-1 infection has been
well documented [46,47]. Surprisingly, it has also been
shown that the CCR5+CD4+ lymphocytes that reside in the
lamina propria of the lower gastrointestinal tract are the
major targets for both simian immunodeficiency virus
(SIV) and HIV-1 replication, independently of the route of
infection [48–53]. These studies demonstrated that up to
60% of CCR5+CD4+ cells can be infected at the peak of
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viraemia, and 80% are depleted within 4 weeks from infec-
tion as a consequence of direct virus replication [51] or
apoptosis [52,53]. It is probably this early and massive
depletion of CD4+ T cell subsets that limits priming of the
immune system and therefore control of HIV-1 infection
during the early and late stages through functional cellular
immune responses.
Recently, several groups have reported on the effect of
ART initiated during AHI on reconstitution of mucosal
lymphoid tissue. Results from these studies have been con-
sistently disappointing and revealed a lack of reconstitution
of lamina propria lymphocytes. In fact, Mehandru and
collaborators studied 18 subjects, nine of whom started
therapy pre-seroconversion and continued treatment for up
to 7 years post-diagnosis [54]. Serial gastrointestinal biopsies
were performed in a subset of these subjects at 1, 2 and
3 years’ post-treatment initiation. Although reconstitution
of CD4+ T cells in the peripheral blood reached 67% at
3 years, the percentage of CD4+ T cells in the mucosa of the
gastrointestinal tract never exceeded 45% of the level
observed in healthy individuals. Moreover, immunohis-
tochemistry analysis of the biopsies revealed that the
immune-inductive sites were fully reconstituted, whereas the
effector sites of the lamina propria were persistently
depleted. This partial reconstitution of the CD4+ and CD8+ T
cell population in the mucosal tract confirmed what had
previously been observed by Guadalupe and collaborators in
a smaller number of individuals (n = 3) during the first
14 months of therapy initiated following seroconversion
[55]. An additional interesting finding by Mehandru and his
group was that activated CD4+ and CD8+ T cells were still
elevated at the mucosal sites after 3–7 years of treatment,
even in the presence of a minimal number of cells expressing
viral mRNA. It has been postulated that the incomplete
reconstitution of resident T cell populations in the lamina
propria may allow a continuous leakage of foreign antigens
from the lumen of the gastrointestinal tract that can persis-
tently activate T cells and predispose them to apoptosis
[54,56]. One premise behind the use of ART is that a high
level of virus replication is the main reason for CD4+ T cell
depletion. However, it has been suggested recently that this
may not be the case and that other co-factors may play an
important role. For example, persistent antigenic stimula-
tion may be a critical factor in the pathogenesis of damage to
mucosal surfaces which, in turn, leads to apoptosis of lym-
phocytes [57]. In this situation, these secondary effects on
the immune system cannot be addressed by ART therapy
alone.
Taken together, these studies indicate that massive deple-
tion of the T lymphocyte pool at the mucosal level takes
place before it is possible to diagnose AHI in most patients,
and certainly prior to initiation of ART. This lag probably
impedes reconstitution or recovery of mucosal T cells, and
could be the major factor preventing recovery from immu-
nological damage sustained during peak HIV-1 replication.
The inevitable consequence is, in most cases, that the
immune system will not be able to control virus replication
upon treatment interruption.
Clinical impact of ART
From a clinical perspective, the effect of ART on patient
outcome may be more favourable overall than that observed
in immunological studies. Hecht and collaborators detected
a trend towards higher CD4 cell counts and lower HIV RNA
levels among 13 people treated with ART during acute HIV
infection when measured 24 weeks after ART interruption, if
therapy was initiated within 2 weeks of seroconversion [27].
Initiation of therapy at a later time-point showed less benefit
in 45 individuals when measured 72 weeks after treatment
interruption. Moreover, there was a substantial decrease in
virus load (approximating a two-thirds-log10 reduction)
observed in the adjusted analysis at 72 weeks among those
who were treated earlier, a reduction which corresponded to
an approximate 50% reduction in the risk of HIV disease
progression over 6 years [58].
Despite the fact that ART initiated during AHI may
not consistently alter the viral set-point following treat-
ment interruption, we need to consider other therapeutic
benefits which may still justify its use: (1) control of symp-
toms related to acute retroviral syndrome; (2) reduction in
viral load which probably decreases the risk of transmis-
sion; (3) potential slowing of the rate of disease progression
among patients with a genetic predisposition; (4) decrease
in the size of the latent HIV pool; (5) possible control of
viraemia and disease progression during which time
advances in therapeutic vaccines and other treatment
modalities may evolve; and (6) possible slowing of the pace
of CD4 cell count decline prior to institution of long-term
ART.
Therefore, despite the fact that initiation of ART during
AHI may not have a significant impact on immune recon-
stitution as currently understood, it may alter clinical out-
comes for those diagnosed during acute HIV-1 infection. As
noted by others, findings which could determine the most
predictive immunological parameters for favourable clinical
outcome have yet to be demonstrated in a randomized clini-
cal trial (RCT) [59]. A randomized controlled trial of treat-
ment versus no treatment in the setting of recent HIV
infection is currently ongoing (ACTG 5217), but will not be
able to address the more probable benefit of ART initiated
during ‘acute’ infection, as most enrolled patients will be
outside the acute infection time-frame by the time therapy is
initiated. Given the challenges of conducting a large ran-
domized study in patients with AHI, it is not likely that
convincing data will be available for guideline development
in the foreseeable future. Thus, the clinical use of ART during
AHI will continue to be based on the best available evidence
and expert opinion. As such, it should still be carefully evalu-
ated on a case-by-case basis.
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